Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,781 total articles

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MediciNova announced that a peer-reviewed study identified MIF-CD74 signaling as a vulnerability in brain metastasis and demonstrated that its drug candidate MN-166 (ibudilast) can pharmacologically inhibit this pathway to suppress metastatic progression. The study supports biomarker-driven clinical strategies, opening new therapeutic avenues for b…

Qfin Holdings Filed 2025 Annual Report on Form 20-F

Qfin Holdings Filed 2025 Annual Report on Form 20-F

Qfin Holdings, a leading AI-driven credit technology platform in China, has filed its 2025 annual report on Form 20-F with the U.S. SEC and published a corresponding report for the Hong Kong Stock Exchange. The reports include audited financial statements and reflect the company's continued efforts in leveraging AI and machine learning to enhance c…

Five Star Bancorp Announces First Quarter 2026 Results

Five Star Bancorp Announces First Quarter 2026 Results

Five Star Bancorp announced its first quarter 2026 financial results, showing net income of $18.6 million, up from $17.6 million in the prior quarter and $13.1 million year-over-year. The company reported improved earnings per share, increased loans and deposits, better net interest margin, and declared an increased cash dividend of $0.25 per share…

Global Ship Lease Announces Annual Meeting of Shareholders

Global Ship Lease Announces Annual Meeting of Shareholders

Global Ship Lease, Inc. announced its Annual Meeting of Shareholders for June 17, 2026, discussing director elections, ratification of its auditing firm, and corporate charter amendments. The company highlighted its fleet status and charter agreements, noting stable contracted revenue and charter durations.

NOV Reports First Quarter 2026 Earnings

NOV Reports First Quarter 2026 Earnings

NOV Inc. announced its first quarter 2026 financial results showing $2.05 billion in revenue, a 2% decrease year-over-year, with net income down to $19 million. Operational challenges due to the Middle East conflict negatively impacted revenue and profitability by approximately $54 million and $32 million respectively. Despite these setbacks, NOV s…

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion announced positive 52-week results from its Phase 2 COVALENT-112 trial evaluating icovamenib in type 1 diabetes patients. The treatment showed a 52% increase in C-peptide levels at 12 weeks in patients diagnosed within 3 years, with durable effects preserved through 52 weeks after only a 12-week dosing period. The drug was well tolera…

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies announced new preclinical data demonstrating that their TSHA-102 gene therapy, based on self-complementary AAV9 delivering a miniaturized MECP2 transgene, achieves approximately 30-fold higher MeCP2 protein expression compared to a single-stranded AAV9 construct in neuronal models. These results validate the design of TSHA-102…

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics announced multiple presentations at the 29th ASGCT Annual Meeting featuring new data on its cardiac gene therapy pipeline, including TNNI3 cardiomyopathy and Friedreich ataxia treatments, as well as advances in AAV manufacturing technology. The presentations highlight the company's innovative approaches and ongoing clinical trial…

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY® (paltusotine) for the treatment of acromegaly in adults, representing the first once-daily oral therapy approved in the EU. This approval is based on robust clinical data from two pivotal Phase 3 trials demonstrating efficacy, safety, and symptom improvement. W…

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio announced multiple presentations at the ASGCT 2026 Annual Meeting showcasing clinical, translational, and manufacturing data on rese-cel, their investigational CAR T cell therapy for autoimmune diseases. Highlights include early clinical data without preconditioning, automated manufacturing advances, and single-cell profiling across v…

Auddia Announces Closing of $12 Million Public Offering

Auddia Announces Closing of $12 Million Public Offering

Auddia Inc., a US-based technology company specializing in AI-driven audio identification and classification, announced the closing of its $12 million public offering. The offering included common stock and warrants, aiming to support the company's working capital and general corporate purposes as it advances its audio AI platform and music promoti…

First Bank Announces First Quarter 2026 Net Income of $7.6 Million

First Bank Announces First Quarter 2026 Net Income of $7.6 Million

First Bank reported first quarter 2026 net income of $7.6 million, down from $9.4 million in the prior year period, driven by elevated credit loss expenses primarily related to its small business portfolio. The bank experienced modest growth in loans and deposits and maintained a strong and stable net interest margin of 3.69%. Despite increased non…

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics announced upcoming presentation of new preclinical data demonstrating its FORCE platform's ability to cross the blood-brain barrier and effectively knockdown MAPT RNA in the central nervous system of nonhuman primates and mice. This breakthrough highlights the platform's potential applications beyond neuromuscular diseases into ne…

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

Voyager Therapeutics announced eight presentations at ASGCT 2026 including a late-breaking oral presentation highlighting the safety and pharmacology of VY1706, its IV-delivered tau-silencing gene therapy targeting Alzheimer's disease. The company plans to submit an IND in Q2 2026 and initiate first-in-human dosing in the second half of 2026. Addit…

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine announced upcoming presentations of new preclinical data for EDIT-401, their lead in vivo CRISPR gene editing candidate, demonstrating its potential as a transformative treatment for hyperlipidemia and related cardiovascular diseases. These presentations will occur across multiple prestigious scientific conferences in May 2026, high…

Montauk Renewables Schedules First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 8:30 a.m. ET

Montauk Renewables Schedules First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 8:30 a.m. ET

Montauk Renewables, a NASDAQ-listed renewable energy company, announced its first quarter 2026 earnings conference call to be held on May 7, 2026. The company specializes in converting biogas into renewable natural gas and renewable electricity, operating multiple projects across several U.S. states. Financial results will be released prior to the …

Hillman Reports First Quarter 2026 Results

Hillman Reports First Quarter 2026 Results

Hillman Solutions Corp. reported a 3.0% increase in net sales to $370.1 million in Q1 2026 but recorded a net loss of $4.7 million. The company completed acquisitions of Campbell Chain & Fittings and Delaney Hardware, expanding its Industrial MRO and Pro Distribution presence. It raised its full-year 2026 net sales guidance while maintaining Adjust…